[HTML][HTML] Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week …
PJ Mease, D van der Heijde, CT Ritchlin… - Annals of the …, 2017 - ard.bmj.com
Objective To assess the safety and efficacy of ixekizumab, a monoclonal antibody that
inhibits interleukin-17A, in a double-blind phase III trial enrolling patients with active …
inhibits interleukin-17A, in a double-blind phase III trial enrolling patients with active …
Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week …
Background Patients who have had inadequate response to tumour necrosis factor
inhibitors have fewer treatment options and are generally more treatment refractory to …
inhibitors have fewer treatment options and are generally more treatment refractory to …
Efficacy and safety of ixekizumab in patients with active psoriatic arthritis: 52-week results from a phase III study (SPIRIT-P1)
D van der Heijde, DD Gladman, M Kishimoto… - The Journal of …, 2018 - jrheum.org
Objective. To evaluate the efficacy and safety of ixekizumab (IXE), an interleukin 17A
antagonist, in patients with psoriatic arthritis (PsA) after 52 weeks in a phase III study …
antagonist, in patients with psoriatic arthritis (PsA) after 52 weeks in a phase III study …
The contribution of joint and skin improvements to the health-related quality of life of patients with psoriatic arthritis: a post hoc analysis of two randomised controlled …
Objective Determine the contribution of joint and skin improvements to health-related quality
of life (HRQoL) in patients with psoriatic arthritis (PsA). Methods SPIRIT-P1 and SPIRIT-P2 …
of life (HRQoL) in patients with psoriatic arthritis (PsA). Methods SPIRIT-P1 and SPIRIT-P2 …
Ixekizumab treatment of biologic-naïve patients with active psoriatic arthritis: 3-year results from a phase III clinical trial (SPIRIT-P1)
V Chandran, D van Der Heijde, RM Fleischmann… - …, 2020 - academic.oup.com
Objective The aim was to assess the safety and efficacy of up to 156 weeks of ixekizumab
(an IL-17A antagonist) treatment in PsA patients. Methods In a phase III study, patients naïve …
(an IL-17A antagonist) treatment in PsA patients. Methods In a phase III study, patients naïve …
Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naïve patients with active psoriatic arthritis (SPIRIT-P1)
AB Gottlieb, V Strand, M Kishimoto, P Mease… - …, 2018 - academic.oup.com
Objective To report patient-reported outcomes of patients with PsA treated with ixekizumab
up to 52 weeks. Methods In SPIRIT-P1, biologic-naïve patients with active PsA were …
up to 52 weeks. Methods In SPIRIT-P1, biologic-naïve patients with active PsA were …
[HTML][HTML] Achieving minimal disease activity in psoriatic arthritis predicts meaningful improvements in patients' health-related quality of life and productivity
Background Although psoriatic arthritis is complex and involves multiple domains, recent
advances in treatments have made remission or near-remission of most symptoms a …
advances in treatments have made remission or near-remission of most symptoms a …
Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naïve …
LC Coates, M Kishimoto, A Gottlieb, CL Shuler… - RMD open, 2017 - rmdopen.bmj.com
Objective To evaluate the efficacy and safety of ixekizumab alone or with concomitant
conventional disease-modifying antirheumatic drugs (cDMARDs) versus placebo in patients …
conventional disease-modifying antirheumatic drugs (cDMARDs) versus placebo in patients …
Treatment patterns and health care costs for patients with psoriatic arthritis on biologic therapy: a retrospective cohort study
B Zhu, E Edson-Heredia, JL Gatz, J Guo, CL Shuler - Clinical therapeutics, 2013 - Elsevier
Background Biologic therapies have been used in patients with psoriatic arthritis (PsA) who
have been inadequately treated with conventional disease-modifying anti-rheumatic drugs …
have been inadequately treated with conventional disease-modifying anti-rheumatic drugs …
Usability of a novel disposable autoinjector device for ixekizumab: results from a qualitative study and an open-label clinical trial, including patient-reported …
K Callis Duffin, M Bukhalo, MA Bobonich… - Medical Devices …, 2016 - Taylor & Francis
Background Most biologic therapies for psoriasis are delivered via subcutaneous injection.
Ixekizumab, an anti-interleukin 17A monoclonal antibody approved for patients with …
Ixekizumab, an anti-interleukin 17A monoclonal antibody approved for patients with …